Sage Rhino Capital LLC Has $1.23 Million Position in Eli Lilly and Company (NYSE:LLY)

Sage Rhino Capital LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,103 shares of the company’s stock after selling 30 shares during the period. Sage Rhino Capital LLC’s holdings in Eli Lilly and Company were worth $1,226,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $35,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $36,000. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LLY. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Bank of America upped their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $731.55.

Eli Lilly and Company Stock Up 6.0 %

Shares of Eli Lilly and Company stock traded up $44.36 during trading hours on Tuesday, reaching $781.56. The company’s stock had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. Eli Lilly and Company has a one year low of $392.26 and a one year high of $800.78. The company has a market capitalization of $742.61 billion, a P/E ratio of 134.43, a P/E/G ratio of 1.60 and a beta of 0.34. The stock’s fifty day simple moving average is $760.89 and its two-hundred day simple moving average is $668.00. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the company posted $2.09 earnings per share. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.